サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1578203

抗糖尿病薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年～2032年の予測

Global Antidiabetics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 170 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
抗糖尿病薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年～2032年の予測
出版日: 2024年09月01日
発行: Value Market Research
ページ情報: 英文 170 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗糖尿病薬市場の世界需要は、2023年の878億米ドルから2032年には約2,612億3,000万米ドルの市場規模に達すると推定され、調査期間2024-2032年のCAGRは12.88%です。

抗糖尿病薬は、糖尿病を患う人々の血糖値を安定させ、コントロールするために導入される医薬品です。抗糖尿病薬は主に糖尿病を管理し、糖尿病患者の状態を維持し、糖尿病発症のリスクを低下させるために使用されます。抗糖尿病薬には、インスリン、プラムリンタイド、ビエッタ、ビクトーザ、経口血糖降下薬（錠剤）などがあります。

市場力学

糖尿病患者の割合の増加とヘルスケア支出の増加は、世界の抗糖尿病薬市場の成長に拍車をかけている基本的な要因です。また、肥満の世界の蔓延は、抗糖尿病薬市場を促進する要因として役立つと期待されています。さらに、様々な参入企業が研究開発投資や製品発売などの事業成長戦略を採用し、抗糖尿病薬市場の成長を後押ししています。さらに、協会や糖尿病学会が認知度を高め、糖尿病コントロールに関する情報を提供するために、啓発・教育プログラムのキャンペーンをいくつか実施していることも、さらなる成長を刺激すると思われます。しかし、インスリンのコストは抗糖尿病薬市場の成長をある程度制限する可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは抗糖尿病薬の世界市場における各セグメントを包括的に評価することもできます。抗糖尿病薬産業の成長と動向は、この調査に全体的なアプローチを提供します。

ご要望がございましたら、弊社までご連絡ください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 抗糖尿病薬- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 抗糖尿病薬の世界市場分析：薬剤クラス別

  • 概要
  • 実績および予測データ分析
  • インスリン（長時間作用型インスリン、プレミックスインスリン、速効型インスリン、ヒトインスリン）
  • GLP-1受容体作動薬
  • DPP-4阻害薬
  • SGLT2阻害薬
  • その他

第6章 抗糖尿病薬の世界市場分析：糖尿病タイプ範囲別

  • 概要
  • 実績および予測データ分析
  • 1型
  • 2型

第7章 抗糖尿病薬の世界市場分析：投与経路範囲別

  • 概要
  • 実績および予測データ分析
  • 経口
  • 皮下
  • 静脈内

第8章 抗糖尿病薬の世界市場分析：流通チャネル範囲別

  • 概要
  • 実績および予測データ分析
  • オンライン薬局
  • 病院薬局
  • 小売薬局

第9章 抗糖尿病薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • セグメント別
    • 国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • セグメント別
    • 国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域売上分析
    • 概要、実績と予測
    • セグメント別
    • 国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • セグメント別
    • 国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • セグメント別
    • 国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第10章 抗糖尿病薬企業の競合情勢

  • 抗糖尿病薬市場の競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • AstraZeneca Plc
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly And Company
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc
  • Novartis AG
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Class Scope (USD MN)
  • Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin) Market Sales By Geography (USD MN)
  • GLP-1 Receptor Agonists Market Sales By Geography (USD MN)
  • DPP- 4 Inhibitors Market Sales By Geography (USD MN)
  • SGLT2 Inhibitors Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Diabetes Type Scope (USD MN)
  • Type 1 Market Sales By Geography (USD MN)
  • Type 2 Market Sales By Geography (USD MN)
  • Analysis By Route of Administration Scope (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Subcutaneous Market Sales By Geography (USD MN)
  • Intravenous Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel Scope (USD MN)
  • Online pharmacies Market Sales By Geography (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail pharmacies Market Sales By Geography (USD MN)
  • Global Antidiabetics Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Antidiabetics Report
  • Market Research Process
  • Market Research Methodology
  • Global Antidiabetics Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Class Scope
  • Market Attractiveness Analysis By Diabetes Type Scope
  • Market Attractiveness Analysis By Route of Administration Scope
  • Market Attractiveness Analysis By Distribution Channel Scope
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Class Scope (USD MN)
  • Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin) Market Sales By Geography (USD MN)
  • GLP-1 Receptor Agonists Market Sales By Geography (USD MN)
  • DPP- 4 Inhibitors Market Sales By Geography (USD MN)
  • SGLT2 Inhibitors Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Diabetes Type Scope (USD MN)
  • Type 1 Market Sales By Geography (USD MN)
  • Type 2 Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration Scope (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Subcutaneous Market Sales By Geography (USD MN)
  • Intravenous Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel Scope (USD MN)
  • Online pharmacies Market Sales By Geography (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail pharmacies Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11218581

The global demand for Antidiabetics Market is presumed to reach the market size of nearly USD 261.23 Billion by 2032 from USD 87.8 Billion in 2023 with a CAGR of 12.88% under the study period 2024-2032.

Antidiabetic drugs are medicines introduced to stabilise and control blood glucose levels in people suffering from diabetes. Antidiabetic drugs are mainly used to manage diabetes and aid diabetic patients in maintaining their condition and lowering their risk of developing diabetes. Antidiabetic drugs include insulin, pramlintide, byetta,victoza and oral hypoglycemics (tablets).

MARKET DYNAMICS

The growing rates of diabetics and rising healthcare expenditure are the fundamental factors that are spurring the growth of the global antidiabetics market. Also, the global prevalence of obesity is expected to serve the antidiabetics market as a driver. Moreover, various significant participants are adopting business growth strategies such as R&D investments and product launches, boosting the antidiabetics market's growth. Furthermore, several campaigns for awareness and education programs created by associations and diabetes societies to raise awareness levels and provide information about diabetes control will stimulate further growth. However, the cost of insulin may limit antidiabetic market growth to some extent.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Antidiabetics. The growth and trends of Antidiabetics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Antidiabetics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class Scope

  • Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin)
  • GLP-1 Receptor Agonists
  • DPP- 4 Inhibitors
  • SGLT2 Inhibitors
  • Others

By Diabetes Type Scope

  • Type 1
  • Type 2

By Route of Administration Scope

  • Oral
  • Subcutaneous
  • Intravenous

By Distribution Channel Scope

  • Online pharmacies
  • Hospital Pharmacies
  • Retail pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antidiabetics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antidiabetics market include AstraZeneca Plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc, Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ANTIDIABETICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class Scope
    • 3.7.2 Market Attractiveness Analysis By Diabetes Type Scope
    • 3.7.3 Market Attractiveness Analysis By Route of Administration Scope
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel Scope
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DRUG CLASS SCOPE

  • 5.1. Overview By Drug Class Scope
  • 5.2. Historical and Forecast Data Analysis By Drug Class Scope
  • 5.3. Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin) Historic and Forecast Sales By Regions
  • 5.4. GLP-1 Receptor Agonists Historic and Forecast Sales By Regions
  • 5.5. DPP- 4 Inhibitors Historic and Forecast Sales By Regions
  • 5.6. SGLT2 Inhibitors Historic and Forecast Sales By Regions
  • 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DIABETES TYPE SCOPE

  • 6.1. Overview By Diabetes Type Scope
  • 6.2. Historical and Forecast Data Analysis By Diabetes Type Scope
  • 6.3. Type 1 Historic and Forecast Sales By Regions
  • 6.4. Type 2 Historic and Forecast Sales By Regions

7. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION SCOPE

  • 7.1. Overview By Route of Administration Scope
  • 7.2. Historical and Forecast Data Analysis By Route of Administration Scope
  • 7.3. Oral Historic and Forecast Sales By Regions
  • 7.4. Subcutaneous Historic and Forecast Sales By Regions
  • 7.5. Intravenous Historic and Forecast Sales By Regions

8. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL SCOPE

  • 8.1. Overview By Distribution Channel Scope
  • 8.2. Historical and Forecast Data Analysis By Distribution Channel Scope
  • 8.3. Online pharmacies Historic and Forecast Sales By Regions
  • 8.4. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 8.5. Retail pharmacies Historic and Forecast Sales By Regions

9. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ANTIDIABETICS COMPANIES

  • 10.1. Antidiabetics Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF ANTIDIABETICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. AstraZeneca Plc
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Bayer AG
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Takeda Pharmaceutical Company Limited
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Eli Lilly And Company
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Boehringer Ingelheim
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Bristol-Myers Squibb
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Pfizer Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Johnson & Johnson Services Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Merck & Co. Inc
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Novartis AG
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies